NO314043B1 - Plasmid eller fagvektor som ikke inneholder en antibiotisk resistens determinant, Pur A-bakterievert som inneholder plasmidet eller vektoren,farmasöytiskpreparat som omfatter bakterien og fremgangsmåte for seleksjon ogopprettholdelse av bakte - Google Patents

Plasmid eller fagvektor som ikke inneholder en antibiotisk resistens determinant, Pur A-bakterievert som inneholder plasmidet eller vektoren,farmasöytiskpreparat som omfatter bakterien og fremgangsmåte for seleksjon ogopprettholdelse av bakte Download PDF

Info

Publication number: NO314043B1
Authority: NO; Norway
Prior art keywords: plasmid; gene; pura; vector; antigen
Prior art date: 1991-05-03

Application number

NO19921729A

Other languages

English (en)

Norwegian (no)

Other versions

NO921729D0 (no

NO921729L (no

Inventor

Iii Robert Newton Brey

James Peter Fulginiti

Algis Anilionis

Original Assignee

American Cyanamid Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-05-03

Filing date

1992-04-30

Publication date

2003-01-20

1992-04-30 Application filed by American Cyanamid Co filed Critical American Cyanamid Co

1992-04-30 Publication of NO921729D0 publication Critical patent/NO921729D0/no

1992-11-04 Publication of NO921729L publication Critical patent/NO921729L/no

2003-01-20 Publication of NO314043B1 publication Critical patent/NO314043B1/no

Links

241000894006 Bacteria Species 0.000 title claims abstract description 59
239000013598 vector Substances 0.000 title claims abstract description 52
230000001580 bacterial effect Effects 0.000 title claims abstract description 44
230000003115 biocidal effect Effects 0.000 title claims abstract description 11
239000013612 plasmid Substances 0.000 title claims description 171
238000000034 method Methods 0.000 title claims description 33
239000003242 anti bacterial agent Substances 0.000 title claims description 10
238000012423 maintenance Methods 0.000 title abstract description 6
239000008194 pharmaceutical composition Substances 0.000 title 1
108090000623 proteins and genes Proteins 0.000 claims abstract description 129
101150002764 purA gene Proteins 0.000 claims abstract description 113
229960005486 vaccine Drugs 0.000 claims abstract description 41
230000002759 chromosomal effect Effects 0.000 claims abstract description 16
108010056443 Adenylosuccinate synthase Proteins 0.000 claims abstract description 12
239000000427 antigen Substances 0.000 claims description 57
108091007433 antigens Proteins 0.000 claims description 57
102000036639 antigens Human genes 0.000 claims description 57
102000004169 proteins and genes Human genes 0.000 claims description 37
241000607142 Salmonella Species 0.000 claims description 35
210000004027 cell Anatomy 0.000 claims description 34
229930024421 Adenine Natural products 0.000 claims description 22
229960000643 adenine Drugs 0.000 claims description 22
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 21
239000013600 plasmid vector Substances 0.000 claims description 19
239000012634 fragment Substances 0.000 claims description 18
241001465754 Metazoa Species 0.000 claims description 17
241000700605 Viruses Species 0.000 claims description 16
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 12
230000015572 biosynthetic process Effects 0.000 claims description 12
108020001507 fusion proteins Proteins 0.000 claims description 12
102000037865 fusion proteins Human genes 0.000 claims description 12
102000005130 adenylosuccinate synthetase Human genes 0.000 claims description 10
230000002950 deficient Effects 0.000 claims description 8
201000004792 malaria Diseases 0.000 claims description 8
239000002773 nucleotide Substances 0.000 claims description 8
125000003729 nucleotide group Chemical group 0.000 claims description 8
230000003612 virological effect Effects 0.000 claims description 8
238000003780 insertion Methods 0.000 claims description 7
230000037431 insertion Effects 0.000 claims description 7
244000045947 parasite Species 0.000 claims description 7
241000588653 Neisseria Species 0.000 claims description 6
241000725643 Respiratory syncytial virus Species 0.000 claims description 6
230000009469 supplementation Effects 0.000 claims description 6
206010061765 Chromosomal mutation Diseases 0.000 claims description 5
101710146739 Enterotoxin Proteins 0.000 claims description 5
150000001491 aromatic compounds Chemical class 0.000 claims description 5
239000000147 enterotoxin Substances 0.000 claims description 5
231100000655 enterotoxin Toxicity 0.000 claims description 5
101710117490 Circumsporozoite protein Proteins 0.000 claims description 4
241000725303 Human immunodeficiency virus Species 0.000 claims description 4
241000702670 Rotavirus Species 0.000 claims description 4
230000002538 fungal effect Effects 0.000 claims description 4
208000002672 hepatitis B Diseases 0.000 claims description 4
230000001937 non-anti-biotic effect Effects 0.000 claims description 4
239000000825 pharmaceutical preparation Substances 0.000 claims description 4
241000711573 Coronaviridae Species 0.000 claims description 3
241000701022 Cytomegalovirus Species 0.000 claims description 3
241000991587 Enterovirus C Species 0.000 claims description 3
241000233866 Fungi Species 0.000 claims description 3
208000005176 Hepatitis C Diseases 0.000 claims description 3
241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 3
241000712079 Measles morbillivirus Species 0.000 claims description 3
241001631646 Papillomaviridae Species 0.000 claims description 3
208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 3
241000710799 Rubella virus Species 0.000 claims description 3
241000607768 Shigella Species 0.000 claims description 3
241000700584 Simplexvirus Species 0.000 claims description 3
241000710772 Yellow fever virus Species 0.000 claims description 3
208000006454 hepatitis Diseases 0.000 claims description 3
231100000283 hepatitis Toxicity 0.000 claims description 3
208000005252 hepatitis A Diseases 0.000 claims description 3
244000052637 human pathogen Species 0.000 claims description 3
230000003071 parasitic effect Effects 0.000 claims description 3
241000701161 unidentified adenovirus Species 0.000 claims description 3
241000712461 unidentified influenza virus Species 0.000 claims description 3
229940051021 yellow-fever virus Drugs 0.000 claims description 3
201000006082 Chickenpox Diseases 0.000 claims description 2
241000606161 Chlamydia Species 0.000 claims description 2
206010064571 Gene mutation Diseases 0.000 claims description 2
210000001744 T-lymphocyte Anatomy 0.000 claims description 2
206010046980 Varicella Diseases 0.000 claims description 2
241000607734 Yersinia <bacteria> Species 0.000 claims description 2
239000002671 adjuvant Substances 0.000 claims description 2
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
238000012258 culturing Methods 0.000 claims description 2
229930182830 galactose Natural products 0.000 claims description 2
230000004060 metabolic process Effects 0.000 claims description 2
238000010187 selection method Methods 0.000 claims description 2
241000193449 Clostridium tetani Species 0.000 claims 1
241000588722 Escherichia Species 0.000 claims 1
241000588747 Klebsiella pneumoniae Species 0.000 claims 1
241000607598 Vibrio Species 0.000 claims 1
238000004519 manufacturing process Methods 0.000 abstract description 36
230000002238 attenuated effect Effects 0.000 abstract description 22
230000035772 mutation Effects 0.000 abstract description 15
238000000855 fermentation Methods 0.000 abstract description 8
230000004151 fermentation Effects 0.000 abstract description 8
241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 abstract description 7
206010061764 Chromosomal deletion Diseases 0.000 abstract description 4
102000005291 Adenylosuccinate synthase Human genes 0.000 abstract description 2
230000027086 plasmid maintenance Effects 0.000 abstract description 2
230000014509 gene expression Effects 0.000 description 33
230000012010 growth Effects 0.000 description 21
239000002609 medium Substances 0.000 description 18
239000000047 product Substances 0.000 description 18
238000009826 distribution Methods 0.000 description 13
230000006641 stabilisation Effects 0.000 description 13
238000011105 stabilization Methods 0.000 description 13
108020004414 DNA Proteins 0.000 description 12
238000010367 cloning Methods 0.000 description 12
230000014616 translation Effects 0.000 description 12
238000010276 construction Methods 0.000 description 11
229930027917 kanamycin Natural products 0.000 description 11
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 11
229960000318 kanamycin Drugs 0.000 description 11
229930182823 kanamycin A Natural products 0.000 description 11
108020004511 Recombinant DNA Proteins 0.000 description 10
230000007547 defect Effects 0.000 description 9
238000012217 deletion Methods 0.000 description 9
230000037430 deletion Effects 0.000 description 9
239000013613 expression plasmid Substances 0.000 description 9
238000001727 in vivo Methods 0.000 description 9
108020004999 messenger RNA Proteins 0.000 description 9
230000010076 replication Effects 0.000 description 9
230000006870 function Effects 0.000 description 8
230000028993 immune response Effects 0.000 description 8
238000011081 inoculation Methods 0.000 description 8
210000000952 spleen Anatomy 0.000 description 8
210000003046 sporozoite Anatomy 0.000 description 8
238000013519 translation Methods 0.000 description 8
241000699670 Mus sp. Species 0.000 description 7
229940124842 Salmonella vaccine Drugs 0.000 description 7
210000000349 chromosome Anatomy 0.000 description 7
230000002068 genetic effect Effects 0.000 description 7
230000002163 immunogen Effects 0.000 description 7
238000000338 in vitro Methods 0.000 description 7
208000015181 infectious disease Diseases 0.000 description 7
210000004185 liver Anatomy 0.000 description 7
230000000717 retained effect Effects 0.000 description 7
238000013518 transcription Methods 0.000 description 7
230000035897 transcription Effects 0.000 description 7
241001167018 Aroa Species 0.000 description 6
108091026890 Coding region Proteins 0.000 description 6
101100491986 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) aromA gene Proteins 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
108091028043 Nucleic acid sequence Proteins 0.000 description 6
108091081024 Start codon Proteins 0.000 description 6
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
230000000890 antigenic effect Effects 0.000 description 6
101150037081 aroA gene Proteins 0.000 description 6
230000027455 binding Effects 0.000 description 6
230000003053 immunization Effects 0.000 description 6
230000010354 integration Effects 0.000 description 6
230000001717 pathogenic effect Effects 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
230000001681 protective effect Effects 0.000 description 6
239000003053 toxin Substances 0.000 description 6
231100000765 toxin Toxicity 0.000 description 6
108700012359 toxins Proteins 0.000 description 6
230000009466 transformation Effects 0.000 description 6
229920001817 Agar Polymers 0.000 description 5
241000282412 Homo Species 0.000 description 5
239000008272 agar Substances 0.000 description 5
239000013604 expression vector Substances 0.000 description 5
239000000203 mixture Substances 0.000 description 5
230000007935 neutral effect Effects 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
108091008146 restriction endonucleases Proteins 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 4
102000053602 DNA Human genes 0.000 description 4
206010059866 Drug resistance Diseases 0.000 description 4
108091081062 Repeated sequence (DNA) Proteins 0.000 description 4
-1 adenine or adenosine Chemical class 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
230000007812 deficiency Effects 0.000 description 4
238000005315 distribution function Methods 0.000 description 4
238000004520 electroporation Methods 0.000 description 4
238000009472 formulation Methods 0.000 description 4
238000002649 immunization Methods 0.000 description 4
230000005847 immunogenicity Effects 0.000 description 4
238000007912 intraperitoneal administration Methods 0.000 description 4
230000014759 maintenance of location Effects 0.000 description 4
239000000463 material Substances 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
238000012261 overproduction Methods 0.000 description 4
244000052769 pathogen Species 0.000 description 4
230000026683 transduction Effects 0.000 description 4
238000010361 transduction Methods 0.000 description 4
230000017105 transposition Effects 0.000 description 4
238000002255 vaccination Methods 0.000 description 4
241001212044 Apura Species 0.000 description 3
239000002126 C01EB10 - Adenosine Substances 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
241001467018 Typhis Species 0.000 description 3
208000037386 Typhoid Diseases 0.000 description 3
239000002253 acid Substances 0.000 description 3
229960005305 adenosine Drugs 0.000 description 3
229940024606 amino acid Drugs 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
229960000723 ampicillin Drugs 0.000 description 3
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
244000052616 bacterial pathogen Species 0.000 description 3
229960001212 bacterial vaccine Drugs 0.000 description 3
239000013602 bacteriophage vector Substances 0.000 description 3
238000011161 development Methods 0.000 description 3
101150002054 galE gene Proteins 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
230000000968 intestinal effect Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
101150066555 lacZ gene Proteins 0.000 description 3
239000003550 marker Substances 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
230000037361 pathway Effects 0.000 description 3
210000001986 peyer's patch Anatomy 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
238000012545 processing Methods 0.000 description 3
230000006798 recombination Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
241000894007 species Species 0.000 description 3
238000012546 transfer Methods 0.000 description 3
201000008297 typhoid fever Diseases 0.000 description 3
230000001018 virulence Effects 0.000 description 3
230000007923 virulence factor Effects 0.000 description 3
239000000304 virulence factor Substances 0.000 description 3
GLDQAMYCGOIJDV-UHFFFAOYSA-N 2,3-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1O GLDQAMYCGOIJDV-UHFFFAOYSA-N 0.000 description 2
ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
101000787278 Arabidopsis thaliana Valine-tRNA ligase, chloroplastic/mitochondrial 2 Proteins 0.000 description 2
101000787296 Arabidopsis thaliana Valine-tRNA ligase, mitochondrial 1 Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
101000787280 Dictyostelium discoideum Probable valine-tRNA ligase, mitochondrial Proteins 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
102000003960 Ligases Human genes 0.000 description 2
108090000364 Ligases Proteins 0.000 description 2
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
241000224017 Plasmodium berghei Species 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
241000702208 Shigella phage SfX Species 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
108010008038 Synthetic Vaccines Proteins 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
102000013625 Valine-tRNA Ligase Human genes 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000004913 activation Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000010171 animal model Methods 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
235000015872 dietary supplement Nutrition 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
239000012737 fresh medium Substances 0.000 description 2
238000007429 general method Methods 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
230000008348 humoral response Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000006698 induction Effects 0.000 description 2
235000013902 inosinic acid Nutrition 0.000 description 2
229920006008 lipopolysaccharide Polymers 0.000 description 2
229940124590 live attenuated vaccine Drugs 0.000 description 2
229940023012 live-attenuated vaccine Drugs 0.000 description 2
210000003563 lymphoid tissue Anatomy 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
229940124551 recombinant vaccine Drugs 0.000 description 2
238000005215 recombination Methods 0.000 description 2
238000011084 recovery Methods 0.000 description 2
210000003705 ribosome Anatomy 0.000 description 2
238000005204 segregation Methods 0.000 description 2
238000013112 stability test Methods 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
238000010189 synthetic method Methods 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
238000001262 western blot Methods 0.000 description 2
ITFICYZHWXDVMU-IPTZIORSSA-N (2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-amino-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-oxopentanoyl]amino]pentanedioic acid Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(=O)O)N ITFICYZHWXDVMU-IPTZIORSSA-N 0.000 description 1
108020004465 16S ribosomal RNA Proteins 0.000 description 1
229940082044 2,3-dihydroxybenzoic acid Drugs 0.000 description 1
108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
235000001674 Agaricus brunnescens Nutrition 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
208000031295 Animal disease Diseases 0.000 description 1
108020004652 Aspartate-Semialdehyde Dehydrogenase Proteins 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
238000011725 BALB/c mouse Methods 0.000 description 1
101100082109 Bacillus subtilis (strain 168) paiB gene Proteins 0.000 description 1
108010077805 Bacterial Proteins Proteins 0.000 description 1
231100000699 Bacterial toxin Toxicity 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000702673 Bovine rotavirus Species 0.000 description 1
241000197194 Bulla Species 0.000 description 1
101150052200 CS gene Proteins 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
241000223924 Eimeria Species 0.000 description 1
241000701832 Enterobacteria phage T3 Species 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
108700039887 Essential Genes Proteins 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
101710082714 Exotoxin A Proteins 0.000 description 1
108010040721 Flagellin Proteins 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241000162682 Heterogen Species 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
241001625930 Luria Species 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
101710085938 Matrix protein Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
101710127721 Membrane protein Proteins 0.000 description 1
241000588655 Moraxella catarrhalis Species 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical group CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
101710116435 Outer membrane protein Proteins 0.000 description 1
201000005702 Pertussis Diseases 0.000 description 1
208000008939 Pneumonic Pasteurellosis Diseases 0.000 description 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
241000655872 Puia Species 0.000 description 1
230000004570 RNA-binding Effects 0.000 description 1
102000004879 Racemases and epimerases Human genes 0.000 description 1
108090001066 Racemases and epimerases Proteins 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
241000701835 Salmonella virus P22 Species 0.000 description 1
241000242678 Schistosoma Species 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
208000019802 Sexually transmitted disease Diseases 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
241000282887 Suidae Species 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
208000000389 T-cell leukemia Diseases 0.000 description 1
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
108010055044 Tetanus Toxin Proteins 0.000 description 1
JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
241001664469 Tibicina haematodes Species 0.000 description 1
102000008579 Transposases Human genes 0.000 description 1
108010020764 Transposases Proteins 0.000 description 1
241000223104 Trypanosoma Species 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
OFBHPPMPBOJXRT-VWJPMABRSA-N adenylosuccinic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C2=NC=NC(N[C@@H](CC(O)=O)C(O)=O)=C2N=C1 OFBHPPMPBOJXRT-VWJPMABRSA-N 0.000 description 1
239000013566 allergen Substances 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
210000003578 bacterial chromosome Anatomy 0.000 description 1
239000000688 bacterial toxin Substances 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
208000002352 blister Diseases 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
230000030570 cellular localization Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000005757 colony formation Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
230000009109 downstream regulation Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000000688 enterotoxigenic effect Effects 0.000 description 1
238000009585 enzyme analysis Methods 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000009313 farming Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
230000008303 genetic mechanism Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
239000006166 lysate Substances 0.000 description 1
230000001320 lysogenic effect Effects 0.000 description 1
229940124735 malaria vaccine Drugs 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
102000042567 non-coding RNA Human genes 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
229940126578 oral vaccine Drugs 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
235000020030 perry Nutrition 0.000 description 1
229940066827 pertussis vaccine Drugs 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
102200082950 rs35685286 Human genes 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940118376 tetanus toxin Drugs 0.000 description 1
235000019157 thiamine Nutrition 0.000 description 1
KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
229960003495 thiamine Drugs 0.000 description 1
239000011721 thiamine Substances 0.000 description 1
238000011426 transformation method Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/68—Stabilisation of the vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Tropical Medicine & Parasitology (AREA)
Mycology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Ultra Sonic Daignosis Equipment (AREA)
Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)

NO19921729A 1991-05-03 1992-04-30 Plasmid eller fagvektor som ikke inneholder en antibiotisk resistens determinant, Pur A-bakterievert som inneholder plasmidet eller vektoren,farmasöytiskpreparat som omfatter bakterien og fremgangsmåte for seleksjon ogopprettholdelse av bakte NO314043B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US69570691A	1991-05-03	1991-05-03

Publications (3)

Publication Number	Publication Date
NO921729D0 NO921729D0 (no)	1992-04-30
NO921729L NO921729L (no)	1992-11-04
NO314043B1 true NO314043B1 (no)	2003-01-20

Family

ID=24794162

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19921729A NO314043B1 (no)	1991-05-03	1992-04-30	Plasmid eller fagvektor som ikke inneholder en antibiotisk resistens determinant, Pur A-bakterievert som inneholder plasmidet eller vektoren,farmasöytiskpreparat som omfatter bakterien og fremgangsmåte for seleksjon ogopprettholdelse av bakte

Country Status (16)

Country	Link
US (2)	US5919663A (da)
EP (1)	EP0512260B1 (da)
JP (1)	JP3320095B2 (da)
KR (1)	KR100242798B1 (da)
AT (1)	ATE202800T1 (da)
AU (1)	AU654347B2 (da)
CA (1)	CA2067862C (da)
DE (1)	DE69231907T2 (da)
DK (1)	DK0512260T3 (da)
ES (1)	ES2160573T3 (da)
FI (1)	FI111013B (da)
GR (1)	GR3036487T3 (da)
IL (1)	IL101751A0 (da)
NO (1)	NO314043B1 (da)
PT (1)	PT512260E (da)
TW (1)	TW201794B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7279313B2 (en) *	1995-09-15	2007-10-09	Centelion	Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
FR2738842B1 (fr) *	1995-09-15	1997-10-31	Rhone Poulenc Rorer Sa	Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
CA2264677A1 (en) *	1996-09-04	1998-03-12	Basf Aktiengesellschaft	Adenylosuccinate synthetase
US6010705A (en) *	1997-04-11	2000-01-04	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Attenuated, invasive vaccines against fish pathogens
AU7105598A (en) *	1997-04-11	1998-11-11	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College, The	Attenuated, invasive vaccines against fish pathogens
MXPA01005615A (es) *	1998-12-04	2004-08-19	Univ Manitoba	Procedimiento de inmunizacion en dos pasos para proteger contra infeccion por chlamydia.
KR100427587B1 (ko) *	2001-01-12	2004-04-27	주식회사 바이오리더스	신규 ｄ-글루탐산 합성효소 유전자 ｄｎａ 및 이를 이용한 항생제 비의존성 벡터
FI116851B (fi) *	2001-05-03	2006-03-15	Fit Biotech Oyj Plc	Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
US20040009937A1 (en) *	2002-01-31	2004-01-15	Wei Chen	Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
CN1646020A (zh) *	2002-01-31	2005-07-27	圣必健公司	将核酸和/或蛋白质导入呼吸系统的方法与制剂
CN1276076C (zh) *	2004-12-14	2006-09-20	华东理工大学	一种鳗弧菌野生毒株的无标记基因缺失减毒突变株及其应用
WO2009025888A2 (en)	2007-05-10	2009-02-26	The Arizona Board Of Regents For And On Behalf Of Arizona State University	Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety
US20100317084A1 (en) *	2007-05-10	2010-12-16	The Arizona Board Of Regents For And On Behalf Of Arizona State University	Recombinant bacteria comprising vectors for expression of nucleic acid sequences encoding antigens
US8465755B2 (en)	2007-10-05	2013-06-18	The Arizona Board Of Regents For And On Behalf Of Arizona State University	Recombinant bacterium capable of eliciting an immune response against enteric pathogens
WO2010045620A1 (en) *	2008-10-17	2010-04-22	The Arizona Board Of Regents For And On Behalf Of Arizona State University	Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
US9163219B2 (en) *	2009-04-14	2015-10-20	Arizona Board Of Regents On Behalf Of Arizona State University	Single expression vector for generation of a virus with a segmented genome
WO2010135563A1 (en)	2009-05-22	2010-11-25	The Arizona Board Of Regents For And On Behalf Of Arizona State University	Recombinant bacterium and methods of antigen and nucleic acid delivery
US9045742B2 (en) *	2009-05-29	2015-06-02	The Arizona Board Of Regents For And On Behalf Of Arizona State University	Recombinant Edwardsiella bacterium
US9062297B2 (en)	2010-01-13	2015-06-23	The Arizona Board Of Regents For And On Behalf Of Arizona State University	Yersinia pestis vaccine
WO2011091291A1 (en)	2010-01-22	2011-07-28	The Arizona Board Of Regents For And On Behalf Of Arizona State University	BACTERIUM COMPRISING A REGULATED rfaH NUCLEIC ACID
US9598697B2 (en)	2010-05-28	2017-03-21	The Arizona Board Of Regents For And On Behalf Of Arizona State University	Recombinant bacterium to decrease tumor growth
WO2012082946A2 (en) *	2010-12-14	2012-06-21	The Regents Of The University Of California	Creation of super-stable coie1 plasmids by duplication of sl 1-4 sequence and point mutations.
US9303264B2 (en)	2012-05-18	2016-04-05	The Arizona Board Of Regents For And On Behalf Of Arizona State University	Photosynthetic microorganisms expressing thermostable lipase
US9580718B2 (en)	2013-06-17	2017-02-28	Arizona Board Of Regents On Behalf Of Arizona State University	Attenuated live bacteria with increased acid resistance and methods of use thereof
KR102006976B1 (ko) *	2019-02-26	2019-08-06	씨제이제일제당 주식회사	신규 프로모터 및 이를 이용한 퓨린 뉴클레오티드 제조방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0025118A1 (de) *	1979-08-18	1981-03-18	Riedlinger, Rainer, Dr.-Ing.	Anordnung zur akustischen Wiedergabe von Signalen, die mittels eines rechten und eines linken Stereo-Kanals darstellbar sind
US4735801A (en) *	1982-09-07	1988-04-05	Board Of Trustees Of Leland Stanford Jr. University	Novel non-reverting salmonella live vaccines
US4550081A (en) *	1980-05-19	1985-10-29	The Board Of Trustees Of The Leland Stanford Jr. University	Non-reverting salmonella
US4837151A (en) *	1980-05-19	1989-06-06	The Board Of Trustees Of The Leland Stanford Junior University, Stanford University	Live vaccines comprising two mutations and foreign antigen
DK410783D0 (da) *	1982-09-16	1983-09-09	Benzon A Salfred	Fremgangsmade til stabilisering af plasmider
EP0251579A3 (en) *	1986-06-24	1989-03-22	Enterovax Research Pty. Ltd.	Non-antibiotic marker system
JP2772793B2 (ja) *	1986-08-05	1998-07-09	トランスジ−ンソシエテアノニム	細菌中に含まれるプラスミドの安定化方法及びこれにより得られる菌株
JPS6427477A (en) *	1987-04-01	1989-01-30	Takeda Chemical Industries Ltd	Dna and use thereof
US5112749A (en) *	1987-10-02	1992-05-12	Praxis Biologics, Inc.	Vaccines for the malaria circumsporozoite protein
GB8730037D0 (en) *	1987-12-23	1988-02-03	Wellcome Found	Vaccines
JPH04504656A (ja) *	1989-03-31	1992-08-20	ワシントンユニバーシティー	ボルデテラワクチン
CA2097931C (en) *	1990-12-18	2003-07-29	Samuel I. Miller, Iii	Salmonella vaccines

1992
- 1992-02-11 TW TW081100950A patent/TW201794B/zh active
- 1992-04-06 DE DE69231907T patent/DE69231907T2/de not_active Expired - Fee Related
- 1992-04-06 PT PT92105887T patent/PT512260E/pt unknown
- 1992-04-06 EP EP92105887A patent/EP0512260B1/en not_active Expired - Lifetime
- 1992-04-06 ES ES92105887T patent/ES2160573T3/es not_active Expired - Lifetime
- 1992-04-06 AT AT92105887T patent/ATE202800T1/de not_active IP Right Cessation
- 1992-04-06 DK DK92105887T patent/DK0512260T3/da active
- 1992-04-28 JP JP13437592A patent/JP3320095B2/ja not_active Expired - Fee Related
- 1992-04-30 IL IL101751A patent/IL101751A0/xx not_active IP Right Cessation
- 1992-04-30 NO NO19921729A patent/NO314043B1/no unknown
- 1992-04-30 FI FI921940A patent/FI111013B/fi not_active IP Right Cessation
- 1992-05-01 CA CA002067862A patent/CA2067862C/en not_active Expired - Fee Related
- 1992-05-01 AU AU15959/92A patent/AU654347B2/en not_active Ceased
- 1992-05-02 KR KR1019920007559A patent/KR100242798B1/ko not_active Expired - Fee Related
1995
- 1995-01-30 US US08/380,297 patent/US5919663A/en not_active Expired - Fee Related
- 1995-05-24 US US08/448,907 patent/US5961983A/en not_active Expired - Fee Related
2001
- 2001-08-31 GR GR20010401346T patent/GR3036487T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
US5919663A (en)	1999-07-06
EP0512260B1 (en)	2001-07-04
AU1595992A (en)	1992-11-05
TW201794B (da)	1993-03-11
CA2067862A1 (en)	1992-11-04
ES2160573T3 (es)	2001-11-16
JP3320095B2 (ja)	2002-09-03
DK0512260T3 (da)	2001-09-17
AU654347B2 (en)	1994-11-03
US5961983A (en)	1999-10-05
FI921940A0 (fi)	1992-04-30
EP0512260A3 (en)	1993-07-28
KR920021701A (ko)	1992-12-18
DE69231907T2 (de)	2001-10-18
CA2067862C (en)	2003-12-30
FI111013B (fi)	2003-05-15
KR100242798B1 (ko)	2000-02-01
ATE202800T1 (de)	2001-07-15
JPH05192161A (ja)	1993-08-03
NO921729D0 (no)	1992-04-30
EP0512260A2 (en)	1992-11-11
IL101751A0 (en)	1992-12-30
PT512260E (pt)	2001-12-28
FI921940L (fi)	1992-11-04
GR3036487T3 (en)	2001-11-30
NO921729L (no)	1992-11-04
DE69231907D1 (de)	2001-08-09

Publication	Publication Date	Title
EP0512260B1 (en)	2001-07-04	Stable pura vectors and uses thereof
AU645489B2 (en)	1994-01-20	Vaccines containing avirulent phoP-type microorganisms
US8318148B2 (en)	2012-11-27	Attenuated bacteria useful in vaccines
NO309331B1 (no)	2001-01-15	Vaksine inneholdende attenuerte bakterier og anvendelse derav
US6413768B1 (en)	2002-07-02	Expression plasmids
AU2002321652A1 (en)	2003-06-19	Attenuated bacteria useful in vaccines
US8137930B2 (en)	2012-03-20	Attenuated Salmonella enterica serovar paratyphi A and uses thereof
EP0485701A1 (en)	1992-05-20	Insertion of DNA by modified transposons
US5874088A (en)	1999-02-23	Deletion mutants of cholera vaccines expressing heterologous antigens
US8475810B2 (en)	2013-07-02	Attenuated Salmonella enterica serovar paratyphi a and uses thereof
AU2001292051B2 (en)	2006-09-14	Stabilisation of plasmid inheritance in bacteria by preventing multimerisation
WO1991018092A1 (en)	1991-11-28	Acid-tolerant salmonella typhi, double aro mutants thereof and use as an oral vaccine for typhoid fever
AU653362B2 (en)	1994-09-29	Insertion of DNA by modified transposons
YUAN et al.	2006	Removal of Antibiotic Resistance of Live Vaccine Strain Escherichia coli MM‐3 and Evaluation of the Immunogenicity of the New Strain
Galen et al.	2004	Attenuated Salmonella and Shigella as live vectors carrying either prokaryotic or eukaryotic expression systems
Nagata et al.	2008	15 Anti-Infective Vaccine Strategies
Kochi et al.	2001	Live attenuated bacterial vectors